Valink is developing a series of novel therapeutics that are more effective at attacking tumours, while sparing healthy tissue.
Location: United States
Total raised: $11.8M
Investors 4
| Date | Name | Website |
| 07.12.2023 | Y Combinat... | ycombinato... |
| 01.07.2025 | Thomas McI... | tgm.com |
| - | Oxonian Ve... | oxonianven... |
| 01.12.2024 | p53 | p53.no |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.10.2025 | - | $11.8M | Redalpine ... |
Mentions in press and media 4
| Date | Title | Description |
| 20.10.2025 | Valink Therapeutics Secures $11.8 Million to Advance Next-Generation Oncology | Valink Therapeutics secured $11.8 million in pre-A funding. This capital accelerates its next-generation oncology pipeline. The company focuses on innovative bispecific antibody-drug conjugates (bsADCs). Its proprietary V-gate technology en... |
| 20.10.2025 | Valink Therapeutics Closes $11.8M Pre-A Financing Round | Valink Therapeutics, Inc., a Cambridge, MA-based biotechnology company developing next-generation oncology therapeutics with a focus on bispecific antibody-drug conjugates (bsADCs) and complementary modalities for improved patient outcomes,... |
| 20.10.2025 | Valink Therapeutics: $11.8 Million Pre-A Funding Secured To Advance Next-Generation Oncology Pipeline | Valink Therapeutics, a biotechnology company developing next-generation oncology therapeutics focused on bispecific antibody-drug conjugates (bsADCs) and complementary treatment modalities, announced the successful closing of an $11.8 milli... |
| - | Valink Therapeutics | “Valink is developing a series of novel therapeutics that are more effective at attacking tumours, while sparing healthy tissue.” |